Endometrial cancer (EC), a widespread gynecological malignancy, has limited therapeutic options, particularly in patients with advanced, metastatic, or recurrent disease.
PCLAF, a proliferation-related protein, is overexpressed in several tumors; however, its role and mechanism in EC remain largely unknown.
